Jump Financial LLC Sells 82,614 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Posted by on Aug 14th, 2023

Jump Financial LLC decreased its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report) by 72.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,010 shares of the biotechnology company’s stock after selling 82,614 shares during the period. Jump Financial LLC’s holdings in ADMA Biologics were worth $103,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GSA Capital Partners LLP purchased a new stake in ADMA Biologics during the 4th quarter valued at approximately $653,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in ADMA Biologics by 391.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 814,836 shares of the biotechnology company’s stock valued at $3,162,000 after buying an additional 649,198 shares in the last quarter. Inspire Investing LLC purchased a new stake in ADMA Biologics during the 1st quarter valued at approximately $540,000. EWG Elevate Inc. purchased a new stake in ADMA Biologics during the 1st quarter valued at approximately $331,000. Finally, Caligan Partners LP purchased a new stake in ADMA Biologics during the 4th quarter valued at approximately $10,383,000. Institutional investors own 74.07% of the company’s stock.

ADMA Biologics Stock Up 3.9 %

NASDAQ ADMA opened at $4.48 on Monday. The company has a quick ratio of 2.73, a current ratio of 6.35 and a debt-to-equity ratio of 1.03. The company has a fifty day moving average of $3.86 and a two-hundred day moving average of $3.65. The firm has a market capitalization of $995.77 million, a price-to-earnings ratio of -22.40 and a beta of 0.79. ADMA Biologics, Inc. has a 52 week low of $2.24 and a 52 week high of $4.64.

ADMA Biologics (NASDAQ:ADMA – Get Free Report) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). The company had revenue of $60.12 million during the quarter, compared to analyst estimates of $55.45 million. ADMA Biologics had a negative net margin of 19.36% and a negative return on equity of 27.55%. During the same period in the previous year, the firm earned ($0.07) earnings per share. On average, analysts predict that ADMA Biologics, Inc. will post -0.09 earnings per share for the current year.

Analysts Set New Price Targets

ADMA has been the subject of a number of research analyst reports. Cantor Fitzgerald increased their price objective on shares of ADMA Biologics from $5.00 to $6.00 and gave the company an “overweight” rating in a report on Thursday. TheStreet raised shares of ADMA Biologics from a “d” rating to a “c-” rating in a report on Friday, May 19th. Mizuho raised their target price on shares of ADMA Biologics from $6.00 to $7.00 in a report on Thursday. Raymond James raised their target price on shares of ADMA Biologics from $5.00 to $6.00 and gave the company a “strong-buy” rating in a report on Thursday. Finally, StockNews.com lowered shares of ADMA Biologics from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.00.

Get Our Latest Report on ADMA Biologics

About ADMA Biologics

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Read More

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.